Osimertinib: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption=' | <StructureSection load='' size='340' side='right' caption='Osimertinib' scene='99/999451/Cv/1'> | ||
Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] tyrosine kinase inhibitor (see [[Receptor tyrosine kinases]]). See also [https://en.wikipedia.org/wiki/Osimertinib Osimertinib]. | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] tyrosine kinase inhibitor (see [[Receptor tyrosine kinases]]). See also [https://en.wikipedia.org/wiki/Osimertinib Osimertinib]. | ||
Osimertinib preferentially binds irreversibly to mutated epidermal growth factor receptor proteins, particularly those with more common mutations in lung cancer such as L858R mutation or an exon 19 deletion.<ref name="a2">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7 "Tagrisso- osimertinib tablet, film coated"]. DailyMed. 5 June 2020. Retrieved 16 October 2020.</ref> | |||
<scene name='99/999451/Overall/1'>Crystal Structure of EGFR(L858R/T790M/C797S) in complex with Osimertinib</scene> ([[6lud]]). | |||
<scene name='99/999451/Binding_site/1'>Osimertinib binding site</scene>. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||